New method for discovering targeted antibody treatments
Official title: Combinatorial pipeline for discovery of anti-GPCR Nanobodies
Funded at Biocognon LLC · NIH-11014847 · Data updated 2026-11-12
This study is working on a new way to find special proteins called nanobodies that can help target and treat diseases, using smart technology to make the process faster and better, which could lead to more effective treatments for patients like you.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biocognon LLC NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $303,024 |
| NIH project number | 1R43GM157811-01 |
| Project ID | NIH-11014847 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions related to G-protein coupled receptors (GPCRs) or those who may benefit from antibody-based therapies.
✕Less likely to help
Patients who do not have conditions related to GPCRs or who are not candidates for antibody therapies may not receive benefit from this research.
What this research studies
This research focuses on developing a novel pipeline for discovering nanobodies, which are a type of antibody that can target specific proteins involved in various diseases. The approach utilizes advanced yeast biosensor technology to screen multiple antigens simultaneously, overcoming limitations of current antibody discovery methods. By integrating bioinformatics and artificial intelligence, the research aims to create high-quality immune reagents that can be used in therapeutic applications. Patients may benefit from more effective and targeted antibody treatments as a result of this innovative methodology.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and targeted antibody therapies for patients.
How similar studies have gone: Other research has shown success with similar combinatorial approaches in antibody discovery, indicating potential for this novel method.
Where this research is happening
-
Biocognon LLC
Pittsburgh, United States Active
Researchers
- Principal investigator: Szent-Gyorgyi, Christopher S — Biocognon LLC
- Study coordinator: Szent-Gyorgyi, Christopher S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.